GT Biopharma's Third Reverse Split in Five Years: Can Financial Engineering Save a Stock That Has Lost 99% of Its Value?
Shares of GT Biopharma shifted sharply as Nasdaq disclosed the company will execute a 1-for-25 reverse stock split effective September 8, 2026 — a move that will consolidate every 25 shares into one, mathematically boosting the per-share price to roughly $7.00 without changing the company's underlying value. The stock popped 10.9% to $0.28, but the bigger picture is far grimmer: this is a company fighting to avoid being kicked off Nasdaq entirely.
• This Is the Third Reverse Split Since 2021 — a Pattern That Screams Trouble
In 2021, GT Biopharma executed a 1-for-17 reverse split.
In February 2024, it did a 1-for-30 split. Now comes a 1-for-25. A company that repeatedly needs to consolidate shares is one whose stock keeps falling back below $1 after each reset. Since its 2018 listing, the stock has lost over 99.9% of its value on a split-adjusted basis. Academic research supports the skepticism: studies document poor performance after reverse splits, with one finding one-year and three-year abnormal returns of −10.76% and −33.90%, respectively.
• The Real Deadline: Nasdaq Delisting Looms by November 16
GT Biopharma received a 180-day extension from Nasdaq on May 20, giving it until November 16, 2026, to get its closing bid price above $1.00 for at least 10 consecutive business days. At $0.28, the stock is nowhere close organically. The reverse split is the company's only viable path to hit that threshold before the deadline.
• A $12 Million Company With No Revenue and a Clinical-Stage Pipeline
GT Biopharma has roughly 45.1 million shares outstanding and a market cap of approximately $12.6 million.
The company reported zero revenue in its most recent quarter and a net loss of $3.1 million.
The sole recent catalyst was dosing its first patient in a solid-tumor trial in May 2026 , but that is years from generating any commercial income.
• The Math Works Temporarily — but History Says It Won't Last Post-split, there will be roughly 1.8 million shares outstanding. For struggling companies, a reverse split often serves as "a temporary fix that doesn't address underlying issues, leading to continued poor performance."
A study of 1,206 reverse-splitting companies found only 500 survived five years. Investors should weigh whether this corporate action is a bridge to real value creation — or the latest chapter in a long decline.